Distinguished in Venous Thromboembolism (VTE)

Guy A. Meyer

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Venous Thromboembolism (VTE)
Paris, FR 
OverviewLocationsClinical Research

Overview

Guy Meyer practices in Paris, France. Mr. Meyer is rated as a Distinguished expert by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Pulmonary Embolism, Venous Thromboembolism (VTE), Deep Vein Thrombosis, Embolectomy, and Thrombectomy.

His clinical research consists of co-authoring 177 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 72 articles and participated in 3 clinical trials in the study of Venous Thromboembolism (VTE).

Gender
Male

Locations

Paris, France
Other Locations
Saint Étienne, France
Saint-etienne-de-valoux, France
Colombes, 92700, France
Saint-etienne, France
Creteil, France
Grenoble, France
Le Mans, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Reduced Dose of Thrombolytic Treatment for Patients With Intermediate High-risk Acute Pulmonary Embolism: a Randomized Controled Trial
A Reduced Dose of Thrombolytic Treatment for Patients With Intermediate High-risk Acute Pulmonary Embolism: a Randomized Controled Trial
Enrollment Status: Recruiting
Publish Date: May 16, 2025
Intervention Type: Drug
Study Drug: Alteplase
Study Phase: Phase 3
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drugs: Apixaban, Rivaroxaban, Heparin, VKA
Study Phase: Phase 3
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Enrollment Status: Completed
Publish Date: August 25, 2022
Intervention Type: Other
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study
Enrollment Status: Completed
Publish Date: July 05, 2022
Intervention Type: Drug
Study Drug: Enoxaparin
Study Phase: Phase 3
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Other
Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study
Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study
Enrollment Status: Completed
Publish Date: May 06, 2021
Intervention Type: Other
Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study PADIS HTP
Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study PADIS HTP
Enrollment Status: Terminated
Publish Date: July 20, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

177 Total Publications

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
Journal: The New England journal of medicine
Published: March 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Meyer's expertise for a condition
ConditionClose
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile